Regeneron Pharmaceuticals | REGN

Stock Price
805.02
Daily Change
-14.07 -1.72%
Monthly
1.13%
Yearly
39.29%
Q4 Forecast
787.95

EPS Reference Time Actual Consensus Previous
2026-10-30 FY2026Q3 AM 13.04 11.83
2026-07-30 FY2026Q2 AM 14.29 10.85 12.89
2026-04-29 FY2026Q1 AM 9.47 9.13 8.22
2026-01-30 FY2025Q4 AM 11.44 10.61 12.07
2025-10-28 FY2025Q3 AM 11.83 9.67 12.46



Peers Price Chg Day Year Date
Kyowa Hakko Kirin 2,412.50 -1.00 -0.04% 4.73% Oct/23
Astellas Pharma 2,512.00 24.50 0.98% 54.73% Oct/23
AbbVie 285.64 0.45 0.16% 25.29% Oct/23
Agenus 6.33 -0.18 -2.77% 52.90% Oct/23
Agios Pharmaceuticals 37.00 -0.19 -0.51% -14.61% Oct/23
Alnylam Pharmaceuticals 224.03 -3.25 -1.43% -51.66% Oct/23
Amgen 439.26 -8.02 -1.79% 50.56% Oct/23
AstraZeneca 12,824.00 -156.00 -1.20% 2.33% Oct/23
Biogen 250.69 -3.15 -1.24% 67.25% Oct/23
BioMarin Pharmaceutical 55.95 -0.68 -1.20% 2.70% Oct/23

Indexes Price Day Year Date
US Index 500 7651 -39.75 -0.52% 11.28% Oct/25
USND 25955 -53.52 -0.21% 11.85% Oct/23
US Index 100 29108 -1.16 -0.004% 12.73% Oct/25

Regeneron Pharmaceuticals traded at $805.02 this Friday October 23rd, decreasing $14.07 or 1.72 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals lost 1.13 percent. Over the last 12 months, its price rose by 39.29 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 787.95 by the end of this quarter and at 738.89 in one year, according to Trading Economics global macro models projections and analysts expectations.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.